Drug Interaction Report
7 potential interactions and/or warnings found for the following 2 drugs:
- estradiol / medroxyprogesterone
- deutivacaftor / tezacaftor / vanzacaftor
Interactions between your drugs
medroxyPROGESTERone tezacaftor
Applies to: estradiol / medroxyprogesterone, deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
MONITOR: Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) or vanzacaftor, tezacaftor, and deutivacaftor may increase the risk for rash events. In one clinical study, the overall incidence of rash events was 10.9% in IVA/TEZ/ELX-treated and 6.5% in placebo-treated patients. The incidence of rash events was 16.3% in females and 5.8% in males for IVA/TEZ/ELX-treated patients and 8.3% in females and 4.8% in males for placebo-treated patients. For IVA/TEZ/ELX-treated patients, the incidence of rash events was 20.5% in females taking a hormonal contraceptive and 13.6% in females not taking a hormonal contraceptive. In other studies, the incidence of rash was 11% in vanzacaftor, tezacaftor, and deutivacaftor treated patients and 7.7% in IVA/TEZ/ELX-treated patients. The incidence of rash was 9.4% in males and 13% in females with vanzacaftor, tezacaftor, and deutivacaftor treatment and 7.6% in males and 7.9% in females with IVA/TEZ/ELX treatment. Rash events were generally mild to moderate in severity with either treatment. The mechanism of this interaction is unknown.
MANAGEMENT: Monitor for rash in patients taking hormonal contraceptives and IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor. Consider interrupting IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.
medroxyPROGESTERone vanzacaftor
Applies to: estradiol / medroxyprogesterone, deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
MONITOR: Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) or vanzacaftor, tezacaftor, and deutivacaftor may increase the risk for rash events. In one clinical study, the overall incidence of rash events was 10.9% in IVA/TEZ/ELX-treated and 6.5% in placebo-treated patients. The incidence of rash events was 16.3% in females and 5.8% in males for IVA/TEZ/ELX-treated patients and 8.3% in females and 4.8% in males for placebo-treated patients. For IVA/TEZ/ELX-treated patients, the incidence of rash events was 20.5% in females taking a hormonal contraceptive and 13.6% in females not taking a hormonal contraceptive. In other studies, the incidence of rash was 11% in vanzacaftor, tezacaftor, and deutivacaftor treated patients and 7.7% in IVA/TEZ/ELX-treated patients. The incidence of rash was 9.4% in males and 13% in females with vanzacaftor, tezacaftor, and deutivacaftor treatment and 7.6% in males and 7.9% in females with IVA/TEZ/ELX treatment. Rash events were generally mild to moderate in severity with either treatment. The mechanism of this interaction is unknown.
MANAGEMENT: Monitor for rash in patients taking hormonal contraceptives and IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor. Consider interrupting IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.
medroxyPROGESTERone deutivacaftor
Applies to: estradiol / medroxyprogesterone, deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
MONITOR: Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) or vanzacaftor, tezacaftor, and deutivacaftor may increase the risk for rash events. In one clinical study, the overall incidence of rash events was 10.9% in IVA/TEZ/ELX-treated and 6.5% in placebo-treated patients. The incidence of rash events was 16.3% in females and 5.8% in males for IVA/TEZ/ELX-treated patients and 8.3% in females and 4.8% in males for placebo-treated patients. For IVA/TEZ/ELX-treated patients, the incidence of rash events was 20.5% in females taking a hormonal contraceptive and 13.6% in females not taking a hormonal contraceptive. In other studies, the incidence of rash was 11% in vanzacaftor, tezacaftor, and deutivacaftor treated patients and 7.7% in IVA/TEZ/ELX-treated patients. The incidence of rash was 9.4% in males and 13% in females with vanzacaftor, tezacaftor, and deutivacaftor treatment and 7.6% in males and 7.9% in females with IVA/TEZ/ELX treatment. Rash events were generally mild to moderate in severity with either treatment. The mechanism of this interaction is unknown.
MANAGEMENT: Monitor for rash in patients taking hormonal contraceptives and IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor. Consider interrupting IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.
Drug and food interactions
tezacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
vanzacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
deutivacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
estradiol food
Applies to: estradiol / medroxyprogesterone
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Mirena
Mirena (levonorgestrel) is a plastic intrauterine device placed in the uterus and is used to ...
Provera
Provera is used for abnormal uterine bleeding, amenorrhea, birth control, endometrial cancer ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Depo Provera
Depo-Provera is used as contraception to prevent pregnancy. It is also used to reduce pain cause by ...
Nexplanon
Nexplanon is a long-term, reversible birth control implant that lasts for three years. Learn about ...
Sprintec
Sprintec is used for abnormal uterine bleeding, birth control, endometriosis, gonadotropin ...
Yaz
Yaz (drospirenone and ethinyl estradiol) is used as a contraceptive to prevent pregnancy. Includes ...
Slynd
Slynd (drospirenone) is a birth control pill used for the prevention of pregnancy. Includes Slynd ...
Lo Loestrin Fe
Lo Loestrin Fe (ethinyl estradiol and norethindrone acetate) birth control tablets are used to ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.